IMPACT THERAP-B

IMPACT Therapeutics, Inc. is a biotechnology company that researches and develops synthetic lethality (SL)-based precision anti-cancer therapies in China and internationally. Its product Senaparib (IMP4297) is a PARP1/2 inhibitor used for first-line maintenance therapy for ovarian cancer. The pipeline includes IMP1734, a next-generation PARP1 selective inhibitor in Phase I/II for advanced solid tumors; IMP9064, an ATR kinase selective inhibitor in Phase I/II for advanced solid tumors; IMP1707, a CNS-penetrant PARP1 selective inhibitor in Phase I for homologous recombination repair tumors; and IMP7068, an advanced WEE1 inhibitor in Phase I/II for advanced solid tumors. Preclinical candidates include IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32. The company was founded in 2009 and is based in Shanghai, China.